Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Operating Expenses (2016 - 2025)

Viking Therapeutics' Operating Expenses history spans 12 years, with the latest figure at $164.7 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 256.28% year-over-year to $164.7 million; the TTM value through Dec 2025 reached $393.3 million, up 160.63%, while the annual FY2025 figure was $393.3 million, 160.63% up from the prior year.
  • Operating Expenses for Q4 2025 was $164.7 million at Viking Therapeutics, up from $98.6 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $164.7 million in Q4 2025 and bottomed at $12.5 million in Q4 2021.
  • The 5-year median for Operating Expenses is $25.5 million (2023), against an average of $38.6 million.
  • The largest annual shift saw Operating Expenses grew 11.04% in 2021 before it surged 256.28% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $12.5 million in 2021, then soared by 62.13% to $20.3 million in 2022, then soared by 44.38% to $29.3 million in 2023, then surged by 57.89% to $46.2 million in 2024, then soared by 256.28% to $164.7 million in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Operating Expenses are $164.7 million (Q4 2025), $98.6 million (Q3 2025), and $74.6 million (Q2 2025).